Drug intelligence / Profile preview

REGN728

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

REGN728 is a monoclonal antibody that was developed by Regeneron Pharmaceuticals and Sanofi. The drug underwent Phase 1 clinical trials in healthy volunteers to assess its safety and tolerability when administered subcutaneously. The specific target and mechanism of action for REGN728 were not publicly disclosed, nor was the intended therapeutic indication. Development of the drug has been discontinued following completion of early-phase studies[1][2][3].

Beyond the preview

Go deeper on REGN728.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN728.

Explore the full profile